ClinicalTrials.gg
TerminatedNCT03207256Updated Jul 21, 2022

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

A Phase 2 interventional study of TGR-1202 and TGR-1202 + Ublituximab in Chronic Lymphocytic Leukemia and Non Hodgkin Lymphoma, sponsored by TG Therapeutics, Inc.. Terminated at 17 sites in United States. Per ClinicalTrials.gov, last updated 2022-07-21.

Sponsored by TG Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Strategic/Business Decision

From the registry’s dates

  • Primary completion was May 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing umbralisib in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. umbralisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
7th of 14
51 · median 51
Started
2017
the only one that year
Phase 2
7 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
10 of 14
TG Therapeutics, Inc.

Among the 14 studies testing umbralisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 2, and was the 9th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 14 studies testing umbralisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About umbralisib

umbralisib: first FDA approval 2021 (UKONIQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing umbralisib in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be currently receiving treatment with ublituximab and/or TGR-1202 on a previously approved protocol.
  • Subjects must have completed at least 6 cycles of therapy on their current protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject progressed while receiving therapy with ublituximab and/or TGR-1202 while participating in their immediate previous trial.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    TGR-1202

    Oral TGR-1202 Daily

    Drug: TGR-1202

  • Experimental
    TGR-1202 + Ublituximab

    Oral TGR-1202 in combination with Ublituximab intravenous administration

    Drug: TGR-1202 + Ublituximab

Interventions

  • Oral Daily TGR-1202

  • DrugTGR-1202 + Ublituximab

    Drug pages: Umbralisib · Ublituximab

    Oral Daily TGR-1202 + Ublituximab IV Administration

06

What researchers measure

Primary outcomes

  1. Adverse Events of TGR-1202 and/or TGR-1202 + ublituximab treatment, including delayed toxicities

    Toxicity according to the investigator (Adverse events with NCI-CTC 4.0)

    Time frame: Evaluated at each planned visit through study completion, an average of 2 years

Secondary outcomes

  1. Progression-free survival of TGR-1202 and/or TGR-1202 + ublituximab treatment

    Date of progression reported for each patient

    Time frame: Evaluated at each planned visit through study completion, an average of 2 years

07

Study locations

17 sites
  • TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805, United States
  • TG Therapeutics Investigational Trial Site
    Tucson, Arizona 85711, United States
  • TG Therapeutics Investigational Trial Site
    Fayetteville, Arkansas 72703, United States
  • TG Therapeutics Investigational Trial Site
    Duarte, California 91010, United States
  • TG Therapeutics Investigational Trial Site
    Fort Myers, Florida 33901, United States
  • TG Therapeutics Investigational Trial Site
    Atlanta, Georgia 30322, United States
  • TG Therapeutics Investigational Trial Site
    Fort Wayne, Indiana 46804, United States
  • TG Therapeutics Investigational Trial Site
    Coon Rapids, Minnesota 55433, United States
  • TG Therapeutics Investigational Trial Site
    Omaha, Nebraska 68198, United States
  • TG Therapeutics Investigational Trial Site
    Durham, North Carolina 27710, United States
  • TG Therapeutics Investigational Site
    Canton, Ohio 44718, United States
  • TG Therapeutics Investigational Trial Site
    Cincinnati, Ohio 45242, United States
  • TG Therapeutics Investigational Trial Site
    Nashville, Tennessee 37203, United States
  • TG Therapeutics Investigational Trial Site
    Denton, Texas 76210, United States
  • TG Therapeutics Investigational Trial Site
    San Antonio, Texas 78229, United States
  • TG Therapeutics Investigational Trial Site
    Seattle, Washington 98104, United States
  • TG Therapeutics Investigational Trial Site
    Milwaukee, Wisconsin 53226, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in May 2022, 57 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2017
First posted
Jul 2, 2017
StartActual
Aug 9, 2017
Primary completionActual
May 25, 2022
CompletionActual
Jun 24, 2022
Last update
Jul 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03207256
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Aug 9, 2017
Primary completion
May 25, 2022
Completion
Jun 24, 2022
Last update
Jul 21, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Umbralisib · Ublituximab

Start the discussion